Profile data is unavailable for this security.
About the company
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
- Revenue in USD (TTM)115.18m
- Net income in USD-36.77m
- Incorporated1997
- Employees374.00
- LocationRxsight Inc100 COLUMBIA STREET, SUITE 120ALISO VIEJO 92656United StatesUSA
- Phone+1 (949) 521-7822
- Fax+1 (302) 655-5049
- Websitehttps://www.rxsight.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adapthealth Corp | 3.26bn | -692.75m | 1.52bn | 10.70k | -- | 1.01 | -- | 0.466 | -5.17 | -5.17 | 24.29 | 11.14 | 0.6714 | 22.22 | 8.12 | 304,741.80 | -14.15 | -4.34 | -15.89 | -4.89 | 18.63 | 18.28 | -21.07 | -6.47 | 0.9438 | 2.17 | 0.5866 | -- | 7.73 | -- | -1,169.99 | -- | -- | -- |
| STAAR Surgical Co | 332.94m | 16.61m | 1.55bn | 1.06k | 94.33 | 3.80 | 70.38 | 4.67 | 0.335 | 0.335 | 6.75 | 8.32 | 0.6984 | 2.13 | 3.54 | 315,286.00 | 3.49 | 6.77 | 3.99 | 7.90 | 79.24 | 76.89 | 4.99 | 9.16 | 5.21 | -- | 0.0003 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Warby Parker Inc | 719.93m | -45.90m | 1.77bn | 2.14k | -- | 5.36 | -- | 2.45 | -0.387 | -0.387 | 6.05 | 2.75 | 1.22 | 5.68 | 603.46 | 336,415.40 | -7.78 | -- | -9.68 | -- | 55.37 | 57.49 | -6.38 | -14.53 | 2.11 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| Novocure Ltd | 549.96m | -168.70m | 1.93bn | 1.45k | -- | 5.33 | -- | 3.51 | -1.58 | -1.58 | 5.13 | 3.35 | 0.4639 | 3.62 | 8.11 | 378,502.40 | -14.23 | -7.74 | -16.44 | -8.95 | 75.83 | 77.22 | -30.67 | -14.69 | 6.22 | -- | 0.6437 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Patterson Companies, Inc. | 6.53bn | 168.41m | 1.96bn | 7.60k | 12.16 | 2.06 | 7.61 | 0.3003 | 1.83 | 1.83 | 71.22 | 10.80 | 2.27 | 5.86 | 15.35 | 859,640.70 | 5.84 | 1.13 | 10.15 | 1.81 | 21.03 | 20.98 | 2.57 | 0.5157 | 0.6723 | 7.91 | 0.4474 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Omnicell Inc | 1.08bn | -20.76m | 2.00bn | 3.65k | -- | 1.66 | 30.90 | 1.85 | -0.4558 | -0.4558 | 23.63 | 26.15 | 0.4818 | 5.64 | 4.20 | 296,013.40 | -0.9258 | 1.73 | -1.12 | 2.25 | 41.63 | 46.69 | -1.92 | 2.92 | 2.22 | -- | 0.322 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| LeMaitre Vascular Inc | 205.62m | 37.68m | 2.03bn | 614.00 | 54.03 | 6.34 | 42.85 | 9.85 | 1.67 | 1.67 | 9.11 | 14.22 | 0.5964 | 1.13 | 7.19 | 334,887.60 | 10.93 | 9.02 | 11.81 | 9.93 | 67.70 | 65.83 | 18.32 | 15.45 | 5.86 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Premier Inc | 1.35bn | 119.54m | 2.04bn | 2.90k | 19.61 | 1.09 | 8.65 | 1.51 | 1.04 | 1.04 | 11.78 | 18.68 | 0.3976 | 5.85 | 3.07 | 464,262.40 | 3.15 | 7.08 | 4.10 | 8.95 | 65.96 | 61.29 | 7.93 | 16.05 | 0.8951 | -- | 0.2775 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Rxsight Inc | 115.18m | -36.77m | 2.13bn | 374.00 | -- | 7.71 | -- | 18.46 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Irhythm Technologies Inc | 537.09m | -131.59m | 2.28bn | 2.00k | -- | 22.99 | -- | 4.25 | -4.26 | -4.26 | 17.40 | 3.18 | 0.7965 | 11.79 | 7.86 | 268,545.50 | -19.51 | -21.92 | -22.66 | -26.77 | 67.19 | 69.39 | -24.50 | -25.75 | 6.76 | -13.78 | 0.8667 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| Conmed Corp | 1.28bn | 98.59m | 2.32bn | 4.00k | 23.89 | 2.63 | 13.62 | 1.82 | 3.15 | 3.15 | 40.81 | 28.61 | 0.5538 | 1.75 | 5.45 | 318,998.30 | 4.28 | 0.8972 | 4.94 | 1.02 | 55.32 | 54.95 | 7.73 | 1.65 | 1.13 | 4.20 | 0.5228 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Enovis Corp | 1.91bn | -107.11m | 2.51bn | 6.55k | -- | 0.7516 | 17.39 | 1.31 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Inari Medical Inc | 547.47m | -57.05m | 2.55bn | 1.30k | -- | 6.02 | -- | 4.67 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| Myriad Genetics, Inc. | 802.20m | -155.20m | 2.57bn | 2.70k | -- | 3.47 | -- | 3.20 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| UFP Technologies Inc | 417.47m | 49.55m | 2.72bn | 3.09k | 55.36 | 8.78 | 44.37 | 6.52 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LivaNova PLC | 1.21bn | -16.59m | 2.78bn | 2.90k | -- | 2.24 | 92.74 | 2.30 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Data as of Sep 19 2024. Currency figures normalised to Rxsight Inc's reporting currency: US Dollar USD
38.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 3.69m | 9.31% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.09m | 5.27% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.92m | 4.84% |
| Lord, Abbett & Co. LLCas of 30 Jun 2024 | 1.74m | 4.37% |
| Artisan Partners LPas of 30 Jun 2024 | 1.33m | 3.36% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.09m | 2.75% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 980.53k | 2.47% |
| Invesco Advisers, Inc.as of 30 Jun 2024 | 844.62k | 2.13% |
| Summit Partners Public Asset Management LLCas of 30 Jun 2024 | 813.83k | 2.05% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 797.58k | 2.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
